BioMarin Pharmaceutical Inc.
BMRN
$66.16
$1.091.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.20% | 9.90% | 12.87% | 12.39% | 18.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.20% | 9.90% | 12.87% | 12.39% | 18.36% |
| Cost of Revenue | 28.02% | 21.12% | 14.52% | 8.73% | -0.25% |
| Gross Profit | -1.29% | 0.97% | 11.44% | 15.98% | 37.37% |
| SG&A Expenses | 20.12% | 8.65% | 2.18% | -2.85% | -0.59% |
| Depreciation & Amortization | 259.99% | -43.73% | -55.18% | -50.47% | -59.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.18% | 14.89% | 8.02% | 2.73% | -1.89% |
| Operating Income | -35.92% | -8.85% | 37.22% | 80.98% | 202.31% |
| Income Before Tax | -82.25% | -42.82% | -10.94% | 73.53% | 181.25% |
| Income Tax Expenses | -58.35% | -22.32% | 16.25% | 129.69% | 334.30% |
| Earnings from Continuing Operations | -88.90% | -48.70% | -18.26% | 61.47% | 156.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.90% | -48.70% | -18.26% | 61.47% | 156.15% |
| EBIT | -35.92% | -8.85% | 37.22% | 80.98% | 202.31% |
| EBITDA | -25.18% | -11.18% | 26.68% | 58.77% | 136.68% |
| EPS Basic | -89.03% | -49.09% | -18.80% | 60.21% | 153.60% |
| Normalized Basic EPS | -41.29% | -6.55% | 35.01% | 76.73% | 188.16% |
| EPS Diluted | -89.02% | -49.15% | -18.99% | 62.63% | 158.99% |
| Normalized Diluted EPS | -40.13% | -5.02% | 37.88% | 79.51% | 192.87% |
| Average Basic Shares Outstanding | 0.81% | 0.85% | 0.93% | 1.02% | 1.10% |
| Average Diluted Shares Outstanding | -1.38% | -1.48% | -1.98% | -0.83% | 0.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |